All In Biotech

Drug Trial Radar · NCT06519370

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

A Phase 3, Open-label, Randomised Study of FDA018-ADC Versus Investigator's Choice of Chemotherapy in Patients Who Recurred During or After Taxane Therapy in Locally Advanced or Metastatic Triple-negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Aug 9, 2024

Primary completion

Aug 18, 2026

Study completion Jun 20, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent inoperable or metastatic Triple-negative Breast Cancer(TNBC) who are resistant to, or recurring during or after taxane therapy.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • FDA018-ADCDrug

    Subjects will receive FDA018-ADC 10 mg/kg of body weight via intravenous(IV) infusion on Day1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.

  • EribulinDrug

    1.4mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle

  • CapecitabineDrug

    1000 to 1250 mg/m\^2 will be administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest

  • GemcitabineDrug

    800 to 1200 mg/m\^2 will be administered IV on day 1 and Day 8 of each 21 day cycle

  • VinorelbineDrug

    25 mg/m\^2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: up to 24 months
  2. Overall Survival (OS)Time frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.